Literature DB >> 26299995

Cathepsin L targeting in cancer treatment.

Dhivya R Sudhan1, Dietmar W Siemann2.   

Abstract

Proteolytic enzymes may serve as promising targets for novel therapeutic treatment strategies seeking to impede cancer progression and metastasis. One such enzyme is cathepsin L (CTSL), a lysosomal cysteine protease. CTSL upregulation, a common occurrence in a variety of human cancers, has been widely correlated with metastatic aggressiveness and poor patient prognosis. In addition, CTSL has been implicated to contribute to cancer-associated osteolysis, a debilitating morbidity affecting both life expectancy and the quality of life. In this review, we highlight the mechanisms by which CTSL contributes to tumor progression and dissemination and discuss the therapeutic utility of CTSL intervention strategies aimed at impeding metastatic progression and bone resorption.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bone resorption; Cancer; Cathepsin L; Metastasis; Protease targeting

Mesh：

Substances：

Year:  2015        PMID： 26299995      PMCID： PMC4624022          DOI： 10.1016/j.pharmthera.2015.08.007

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN： 0163-7258            Impact factor:   12.310


  202 in total

Review 1.  Metastasis to bone: causes, consequences and therapeutic opportunities.

Authors:  Gregory R Mundy
Journal:  Nat Rev Cancer       Date:  2002-08       Impact factor: 60.716

Review 2.  Development of cathepsin inhibitors and structure-based design of cathepsin B-specific inhibitor.

Authors:  Koji Tomoo
Journal:  Curr Top Med Chem       Date:  2010       Impact factor: 3.295

3.  The tumor promoter phorbol 12-myristate 13-acetate induces a program of altered gene expression similar to that induced by platelet-derived growth factor and transforming oncogenes.

Authors:  M S Rabin; P J Doherty; M M Gottesman
Journal:  Proc Natl Acad Sci U S A       Date:  1986-01       Impact factor: 11.205

4.  Initial evaluation of the antitumour activity of KGP94, a functionalized benzophenone thiosemicarbazone inhibitor of cathepsin L.

Authors:  Gustavo E Chavarria; Michael R Horsman; Wara M Arispe; G D Kishore Kumar; Shen-En Chen; Tracy E Strecker; Erica N Parker; David J Chaplin; Kevin G Pinney; Mary Lynn Trawick
Journal:  Eur J Med Chem       Date:  2012-10-29       Impact factor: 6.514

5.  Prostate cancer mediates osteoclastogenesis through two different pathways.

Authors:  Hitoshi Inoue; Kazuo Nishimura; Daizo Oka; Yasutomo Nakai; Masahiro Shiba; Takashi Tokizane; Yasuyuki Arai; Masashi Nakayama; Kiyonori Shimizu; Natsuki Takaha; Norio Nonomura; Akihiko Okuyama
Journal:  Cancer Lett       Date:  2005-06-01       Impact factor: 8.679

6.  Antisense RNA inhibition of cathepsin L expression reduces tumorigenicity of malignant cells.

Authors:  H Kirschke; R Eerola; V K Hopsu-Havu; D Brömme; E Vuorio
Journal:  Eur J Cancer       Date:  2000-04       Impact factor: 9.162

7.  Cathepsin L in secretory vesicles functions as a prohormone-processing enzyme for production of the enkephalin peptide neurotransmitter.

Authors:  Sukkid Yasothornsrikul; Doron Greenbaum; Katalin F Medzihradszky; Thomas Toneff; Richard Bundey; Ruthellen Miller; Birgit Schilling; Ivonne Petermann; Jessica Dehnert; Anna Logvinova; Paul Goldsmith; John M Neveu; William S Lane; Bradford Gibson; Thomas Reinheckel; Christoph Peters; Matthew Bogyo; Vivian Hook
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-17       Impact factor: 11.205

Review 8.  Microenvironmental regulation of metastasis.

Authors:  Johanna A Joyce; Jeffrey W Pollard
Journal:  Nat Rev Cancer       Date:  2008-03-12       Impact factor: 60.716

9.  Cathepsin L-deficient mice exhibit abnormal skin and bone development and show increased resistance to osteoporosis following ovariectomy.

Authors:  Wendy Potts; Jonathan Bowyer; Huw Jones; David Tucker; Anthony J Freemont; Andrew Millest; Colin Martin; Wendy Vernon; Diane Neerunjun; Gillian Slynn; Fiona Harper; Rose Maciewicz
Journal:  Int J Exp Pathol       Date:  2004-04       Impact factor: 1.925

10.  Cathepsin L increases invasion and migration of B16 melanoma.

Authors:  Zhen Yang; James L Cox
Journal:  Cancer Cell Int       Date:  2007-05-08       Impact factor: 5.722
View more
  45 in total

1.  Affinity-Enhanced Luminescent Re(I)- and Ru(II)-Based Inhibitors of the Cysteine Protease Cathepsin L.

Authors:  Matthew Huisman; Jacob P Kodanko; Karan Arora; Mackenzie Herroon; Marim Alnaed; John Endicott; Izabela Podgorski; Jeremy J Kodanko
Journal:  Inorg Chem       Date:  2018-06-08       Impact factor: 5.165

2.  Cathepsin L in tumor angiogenesis and its therapeutic intervention by the small molecule inhibitor KGP94.

Authors:  Dhivya R Sudhan; Maria B Rabaglino; Charles E Wood; Dietmar W Siemann
Journal:  Clin Exp Metastasis       Date:  2016-04-07       Impact factor: 5.150

3.  EnABLing Cathepsin-Driven Melanoma Metastasis.

Authors:  Rakshamani Tripathi; Rina Plattner
Journal:  Mol Cell Oncol       Date:  2018-08-17

4.  Cathepsin L inactivation leads to multimodal inhibition of prostate cancer cell dissemination in a preclinical bone metastasis model.

Authors:  Dhivya R Sudhan; Christine Pampo; Lori Rice; Dietmar W Siemann
Journal:  Int J Cancer       Date:  2016-02-05       Impact factor: 7.396

5.  The Identification of Macrophage-enriched Glycoproteins Using Glycoproteomics.

Authors:  Jelani C Zarif; Weiming Yang; James R Hernandez; Hui Zhang; Kenneth J Pienta
Journal:  Mol Cell Proteomics       Date:  2017-03-27       Impact factor: 5.911

6.  Peptidomimetic Vinyl Heterocyclic Inhibitors of Cruzain Effect Antitrypanosomal Activity.

Authors:  Bala C Chenna; Linfeng Li; Drake M Mellott; Xiang Zhai; Jair L Siqueira-Neto; Claudia Calvet Alvarez; Jean A Bernatchez; Emily Desormeaux; Elizabeth Alvarez Hernandez; Jana Gomez; James H McKerrow; Jorge Cruz-Reyes; Thomas D Meek
Journal:  J Med Chem       Date:  2020-03-17       Impact factor: 7.446

7.  Caging the uncageable: using metal complex release for photochemical control over irreversible inhibition.

Authors:  Matthew Huisman; Jessica K White; Veronica G Lewalski; Izabela Podgorski; Claudia Turro; Jeremy J Kodanko
Journal:  Chem Commun (Camb)       Date:  2016-10-18       Impact factor: 6.222

Review 8.  Targeting eukaryotic proteases for natural products-based drug development.

Authors:  Fatma H Al-Awadhi; Hendrik Luesch
Journal:  Nat Prod Rep       Date:  2020-06-24       Impact factor: 13.423

9.  Increasing time on target: utilization of inhibitors of cysteine cathepsins to enhance the tumor retention of receptor-targeted agents.

Authors:  Wei Fan; Wenting Zhang; Sameer Alshehri; Jered C Garrison
Journal:  Chem Commun (Camb)       Date:  2018-10-04       Impact factor: 6.222

10.  Abl and Arg mediate cysteine cathepsin secretion to facilitate melanoma invasion and metastasis.

Authors:  Rakshamani Tripathi; Leann S Fiore; Dana L Richards; Yuchen Yang; Jinpeng Liu; Chi Wang; Rina Plattner
Journal:  Sci Signal       Date:  2018-02-20       Impact factor: 8.192
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.